Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.
Hematology/Oncology June 8th 2026
Oncology News Central (ONC)
“Emerging data from this confirmatory study have highlighted a safety profile that is unfavorable compared to that previously observed in clinical evaluation.” — Christelle Huguet, PhD, Ipsen
Hematology/Oncology March 17th 2026
The brothers falsely inflated OP-1250’s overall response rate from 9% to 17% and bumped up the expected phase II response rate from 18% to 36%.
Oncology Pharmacy February 2nd 2026
Epoch Health
“Patients and doctors [lack] enough research to inform medical guidelines and many patients are using these products without talking to their doctor about them.” —Senior White House official
Family Medicine/General Practice January 21st 2026
Providers nationwide are experiencing an uptick in health plans denying payments by improperly asserting that providers are not coding their claims correctly.
Hematology/Oncology November 17th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS